he CINtec PLUS Cytology duel-stain biomarker technology was found to be more sensitive than Pap in detecting cervical precancer in women with HPV.
Sara Karlovitch
Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.
Articles by Sara Karlovitch
Emergency Use Authorization granted for young children may address cases of severe disease, which is more common in pediatric patients with cancer compared with children without cancer.
Sergio A. Giralt, MD, discusses the key goals of the SIERRA trial which evaluated the safety and efficacy of I apamistamab versus conventional chemotherapy for the treatment of older patients with relapsed/refractory acute myeloid leukemia.
Joseph M. Curry, MD, discussed the efficacy of durvalumab in combination with metformin for the treatment of squamous cell carcinoma of the head and neck during an interview with Targeted Oncology.
The trial is evaluating the safety and efficacy of taletrectinib in ROS1 NSCLC. Taletrectinib is a novel TKI.
Two approvals for asciminib were issued by the FDA for the treatment of CML with a Ph+ mutation.
Jesús García-Foncillas, MD, PhD, discussed the comparison of larotrectinib versus entrectinib for the treatment of NTRK fusion-positive tumors in an interview with Targeted OncologyTM.
While some studies have found that obesity provides a survival advantage in certain cancers, sarcopenia obesity was found to be associated with worse survival outcomes in patients with endometrial cancer.
NBTXR3, which is activated by radiotherapy, was found to be safe and tolerable in frail patients with head and neck squamous cell carcinoma. The agent can be used on its own or in combination with other immunotherapy agents.
Lead investigator Arndt Vogel, MD, discussed the use of immunotherapy in earlier-stage HCC and findings from the IMMUTACE in an interview with Targeted Oncology.
Patients with advanced ovarian cancer who respond to platinum-based chemotherapy are eligible for olaparib monotherapy. Data from the SOLO1 trial found that the safety profile of the agent is manageable.
Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology.
The trial is designed to evaluate eltanexor monotherapy in high-risk MDS. It is recruiting in 8 separate states.
In an interview with Targeted Oncology, study investigator David Dawe, MD, BASc, MSC, FRCPC, discussed the impact of age, comorbidities, and polypharmacy on cancer care in greater detail.
Melphalan flufenamide is being removed from the US market after the OCEAN study failed to show an improvement in OS over pomalidomide and dexamethasone. The agent was granted approval for use in R/R MM in February.
Adding the oral mutant isocitrate dehydrogenase-2 inhibitor enasidenib to azacitidine helps to extend ORR in patients with AML, compared to azacitidine monotherapy.
During a recent tweet chat with Sheena Mukkada, MD, MPH, an assistant member of the St. Jude Children’s Research Hospital, joined Targeted Oncology to discuss how the COVID-19 pandemic has impacted pediatric cancer care.
The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in postmenopausal patients with breast cancer.
The assay is meant to determine patient eligibility for atezolizumab, which was granted FDA approval in PD-L1-positive lung cancer on October, 15. The assay was used in the IMpower010 study.
A fast-track designation was granted to a universal cancer vaccine in combination with checkpoint inhibitors. The vaccine, UV1, can be used in combination with either pembrolizumab or ipilimumab.
A trial is currently recruiting across the US to investigate the safety of a new anti-PD-1/CD3 antibody for the treatment of relapsed or refractory T-cell lymphoma. It aims to enroll 86 patients.
The primary end point of the ROMAN trial was not reached after avasopasem was found to not significantly reduce the incidence of severe oral mucositis. A full analysis of the results is ongoing.
Sarah P. Psutka, MD, discussed the efficacy and toxicity of later-line ICI and TKI therapy in mRCC during an interview with Targeted Oncology.
N-803 in combination with BCG has demonstrated disease-free survival benefit in patients with NMIBC. This meets the primary end point of the QUILT 3.032 study.
In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.
A study at MD Anderson Cancer Center aims to evaluate ixazomib and rituximab in patients with relapsed or refractory mantle cell lymphoma.
In combination with chemotherapy and sintilimab, a bevacizumab biosimilar injection was found to increase PFS in patients with Nonsquamous NSCLC who progressed after a prior EGFR-TKI.
Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.
In an interview with Targeted Oncology, Annette S. Kim, MD, PhD, discussed the updates to the NCCN guidelines on myeloid/lymphoid neoplasms with eosinophilia, along with how to bring new pathology strategies for these disease into clinical practice.
During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma.